What records are connected here?
- Evidence lanes
- 1
- Source years
- 7
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2Evidence: Smaller human trialsHormones
Also called Pralmorelin, Growth hormone-releasing peptide 21
GHRP-2 (growth hormone-releasing peptide 2) is a synthetic six-amino-acid peptide that FDA’s substance registry lists under the international name pralmorelin.1 In small human studies it raised growth hormone levels and appetite, and Japanese researchers have tested it as a diagnostic test for adult growth hormone deficiency.6,7 FDA has placed GHRP-2 in category 2 of its 503B compounding list, for substances that may present significant safety risks, citing possible immune reactions and reports of serious adverse events, though causality has not been established. Its 503A nominations list places GHRP-2 in category 3, nominated without adequate support.2,5 No FDA approval is reported in the sources reviewed here, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4
| What it is | A synthetic hexapeptide amide (D-Ala-D-2-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2), also recorded as pralmorelin and KP-102, according to FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. Since September 29, 2023, FDA has listed GHRP-2 in category 2 under its interim policy for outsourcing facilities, and its 503A nominations list, updated May 14, 2026, places it in category 3.2,5 |
| Human evidence | A small randomized, placebo-controlled study of growth hormone and appetite, and a diagnostic study comparing people with and without growth hormone deficiency. FDA also reports serious adverse events in patients who received GHRP-2.2,6,7 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
GHRP-2 is a synthetic peptide of six amino acids, several of them in the unnatural D form, ending in an amide. FDA’s substance registry records it as pralmorelin, growth hormone-releasing peptide 2 and KP-102.1
FDA notes that GHRP-2 contains an unnatural amino acid, which makes the peptide harder to characterize.2
Its registered name, growth hormone-releasing peptide 2, describes its intended action of prompting the release of growth hormone.1
The authors of a 2006 study describe it as a growth hormone secretagogue that acts like ghrelin, a hormone that stimulates appetite, and report that it raised both growth hormone levels and food intake.7
In a 2006 double-blind, randomized, placebo-controlled study, 19 healthy lean and obese adults ate more at a buffet meal after GHRP-2 than after placebo: about 10% more at the lower level tested and about 34% more at the higher. Growth hormone rose in all participants.7
In a 2007 Japanese study of 77 healthy people and 58 patients with severe growth hormone deficiency, peak growth hormone after GHRP-2 was far lower in the patients, and the authors proposed a cut-off for diagnosing the deficiency.6
FDA reports being aware of serious adverse events in patients who received GHRP-2, including a greater need for insulin to control blood sugar, deaths of critically ill study participants, infection and pancreatitis, though causality has not been established.2
These studies measured short-term hormone and appetite responses. The sources reviewed here do not show that GHRP-2 is effective or safe as a treatment for any condition.2,6,7
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of GHRP-2 by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-2 in category 2 under the interim policy for outsourcing facilities (section 503B) for certain routes since September 29, 2023, citing possible immune reactions from aggregation and impurities.2
FDA’s list of bulk drug substances nominated for pharmacy compounding under section 503A, updated May 14, 2026, places GHRP-2 in category 3: substances nominated without adequate support.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHRP-2 is not among them.3,4
Whether it is effective for any condition: the human studies reviewed here measured short-term hormone and appetite responses or tested it as a diagnostic.6,7
Whether the serious adverse events FDA describes were caused by GHRP-2, which FDA states has not been established.2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for GHRP-2: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for GHRP-2 are a bounded selection, not every registration or paper about GHRP-2. For the years before GHRP-2 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list GHRP-2 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name GHRP-2 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; on FDA’s compounding safety-risk list (category 2). Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; on FDA’s compounding safety-risk list (category 2). Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date February 12, 2025
Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats.↗Source date February 12, 2025Literature metadata · added November 15, 2026
Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder.↗Source date July 16, 2022Literature metadata · added November 15, 2026
Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells.↗Source date July 16, 2022PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
21 of 21 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.
PubMed lists PMID 10195374 in Journal of endocrinological investigation as Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 1999-02 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 15230633 in Drugs in R&D as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
21 with attributed title, venue, publication-date, and type metadata.
Selected records span January 23, 2008 to February 12, 2025. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 16033952 in Drug metabolism and disposition: the biological fate of chemicals as Journal Article, with publication-date metadata of 2005-07-20 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35795807 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2022-06-06 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9798733 in Endocrine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1998-08 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20045717 in Peptides as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-01-05 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 27020037 in Endocrine journal as Controlled Clinical Trial, Journal Article, with publication-date metadata of 2016-03-26 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 33197153 in Drug testing and analysis as Journal Article, Validation Study, with publication-date metadata of 2020-11-25 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 20552695 in Rapid communications in mass spectrometry : RCM as Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-07-30 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24446112 in Drug testing and analysis as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-01-20 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18493103 in Endocrine journal as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-05-21 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 8886623 in Endocrine journal as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1996-06 (month precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 9096259 in Life sciences as Comparative Study, Journal Article, with publication-date metadata of 1997 (year precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 25761386 in AAPS PharmSciTech as Journal Article, with publication-date metadata of 2015-03-12 (day precision). PeptideScanner associated the retained record with the identity slug ghrp-2. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
European Journal of Endocrinology · Official source · Source checked November 16, 2026
Obesity · Official source · Source checked November 16, 2026